ID: ALA3608980

Max Phase: Preclinical

Molecular Formula: C17H13ClN2O2S

Molecular Weight: 344.82

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc(Nc2ncc(C(=O)c3ccccc3Cl)s2)cc1

Standard InChI:  InChI=1S/C17H13ClN2O2S/c1-22-12-8-6-11(7-9-12)20-17-19-10-15(23-17)16(21)13-4-2-3-5-14(13)18/h2-10H,1H3,(H,19,20)

Standard InChI Key:  ZTZPUVXXDCDDKO-UHFFFAOYSA-N

Associated Targets(Human)

MAP kinase p38 1586 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 344.82Molecular Weight (Monoisotopic): 344.0386AlogP: 4.78#Rotatable Bonds: 5
Polar Surface Area: 51.22Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.49CX Basic pKa: 1.60CX LogP: 4.79CX LogD: 4.79
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.68Np Likeness Score: -1.66

References

1. Park H, Lee S, Hong S..  (2015)  Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.,  25  (18): [PMID:26259807] [10.1016/j.bmcl.2015.07.094]

Source